Strategic Signals Weekly
Licensing deals, strategic reviews, and financing events from regulatory filings. Part of the RxDataLab platform: clinical trials, SEC filings, and hedge fund positioning, linked by company.
Get in Touch
Interested in this coverage?
Reach out with questions or to discuss what you're tracking.
or email [email protected]
Weekly Signal Volume
Licensing & Partnerships
New collaboration agreements, licensing deals, and partnership announcements.
| Filed | Company |
|---|---|
| Sep 3 | Teva Pharmaceuticals (TEVA) Teva Pharmaceutical Industries Limited reported receiving $500 million in development milestone payments during Q4 2025. These payments were triggered by the initiation of Phase 3 studies for duvakitug (anti-TL1A). Drug: duvakitug (anti-TL1A) [SEC] |
Financing Events
Capital raises, ATM programs, debt offerings, and other financing activities.
| Filed | Company |
|---|---|
| Sep 4 | Senti Biosciences, Inc. (SNTI) Senti Biosciences Holdings, Inc. announced two financing events. Its subsidiary, Senti Holdings, completed the sale of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund, L.P. Additionally, the Company entered into an equity commitment letter with an affiliate of Celadon Partners, LLC for the purchase of $2.5 million of its common stock, contingent on the closing of a merger. [SEC] |
| Sep 3 | PASSAGE BIO INC (PASG) Passage Bio amended its merger agreement with Remix Therapeutics, Inc. to facilitate a two-step merger structure and allow for the issuance of pre-funded warrants in a concurrent private placement. This private placement, totaling approximately $70.0 million, will fund immediately prior to the merger's first step through the sale of Remix common stock and/or pre-funded warrants to accredited investors. All other economic terms of the original merger agreement, including the aggregate equity value, remain unchanged. [SEC] |
| Sep 2 | PMV Pharmaceuticals, Inc. (PMVP) PMV Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of common stock and warrants, expecting net proceeds of approximately $47.0 million. The company intends to use these funds, along with existing cash, to finance late-stage clinical development, regulatory submission, and commercialization preparation for rezatapopt, a treatment for platinum-resistant/refractory ovarian cancer harboring a TP53 Y220C mutation, extending their cash runway into the first quarter of 2028. [SEC] |
| Sep 2 | Senti Biosciences, Inc. (SNTI) Senti Biosciences Holdings, Inc. amended its Securities Purchase Agreement to authorize the issuance and sale of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund, L.P., which also satisfies a previous obligation from Celadon Partners. Separately, the company received notices from Nasdaq regarding non-compliance with minimum bid price and stockholders' equity requirements, initiating a process to regain compliance to avoid delisting. The company is considering a reverse stock split and submitting a compliance plan to Nasdaq. [SEC] |
| Sep 2 | INTELLIGENT BIO SOLUTIONS INC. Intelligent Bio Solutions Inc. completed a private placement offering, raising approximately $5.0 million in gross proceeds. The company sold 2,036,659 pre-funded warrants, along with Series N-1 and N-2 warrants, to a single institutional investor. The net proceeds are intended for working capital and general corporate purposes. [SEC] |
| 6 more on the RxDataLab platform | |
About This Data
These events are extracted from SEC 8-K filings using keyword detection across the full filing text. Summaries are generated automatically from the filing content to describe what happened in plain language. We track five categories:
- FDA Actions (CRL): Companies that received a Complete Response Letter from the FDA, the agency's formal notice that a drug application cannot be approved as submitted.
- PDUFA Dates: Upcoming FDA decision deadlines disclosed via 8-K. A PDUFA date is the statutory deadline by which the FDA must complete its review of a new drug application.
- Strategic Reviews: Companies disclosing that they are exploring "strategic alternatives," potential sales, or board-level reviews of company direction.
- Licensing Deals: Material definitive agreements involving licensing, collaboration, or partnership arrangements. Requires multiple keyword matches to reduce noise.
- Financing Events: Capital raises, ATM offerings, registered direct transactions, and debt issuances. Filing proceeds are extracted where disclosed.
On the RxDataLab platform, each event is cross-referenced with the company's clinical trial pipeline, insider trading activity, and financials.
Data from RxDataLab and SEC EDGAR.